Haemonetics Reaffirms Fiscal 2025 Guidance: Projects Adjusted Earnings Per Diluted Share Of $4.45-$4.75 Vs. $4.6 Estimate
Portfolio Pulse from Benzinga Newsdesk
Haemonetics has reaffirmed its fiscal 2025 guidance, projecting adjusted earnings per diluted share of $4.45-$4.75, compared to the $4.6 estimate.
August 08, 2024 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics has reaffirmed its fiscal 2025 guidance, projecting adjusted earnings per diluted share of $4.45-$4.75, which is in line with the $4.6 estimate.
The reaffirmation of guidance within the expected range is likely to instill confidence among investors, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100